Anti-cancer vaccine ilixadencel plus sunitinib show promise for untreated metastatic kidney cancer

A phase 2 clinical trial with a new treatment called ilixadencel in combination with sunitinib has shown to improve overall survival in newly diagnosed patients with metastatic renal cell carcinoma (RCC). People given the combination treatment lived 10 months longer than those on sunitinib alone, suggesting that ilixadencel aids survival in these patients. Ilixadencel is […]

read more

Ilixadencel granted Regenerative Medicine Advanced Therapy by FDA for metastatic kidney cancer

The US Food and Drug Administration (FDA) has designated ilixadencel a Regenerative Medicine Advanced Therapy (RMAT) as a treatment for metastatic renal cell carcinoma (RCC). This designation is similar to the FDA’s Breakthrough Therapy Designation, and recognises the therapeutic potential of ilixadencel as well as the unmet patient need for viable therapies for this difficult-to-treat […]

read more

Ilixadencel improves responses and survival in metastatic kidney cancer

Results from a recent phase 2 clinical trial of ilixadencel plus sunitinib for the treatment of  newly-diagnosed metastatic renal cell carcinoma (RCC) were presented at the 2020 American Society of Clinical Oncology (ASCO)/Society for Immunotherapy of cancer (SITC) Clinical Immuno-Oncology Symposium, in Orlando, Florida, in February. Ilixadencel is an immune primer designed to increase the body’s […]

read more

Ilixadencel plus sunitinib combination for metastatic kidney cancer

A combination of ilixadencel plus sunitinib has shown a complete tumour response in patients with metastatic renal cell carcinoma (RCC) in a recent phase 2 clinical trial. Ilixadencel is an off-the-shelf immune primer for the treatment of solid tumours. The clinical trial assessed the effectiveness of combining ilixadencel with sunitinib in 88 untreated patients with […]

read more

Cancer vaccine ilixadencel triggers strong immune response in newly diagnosed kidney cancer tumours

Results from the first phase of a phase 1/2 clinical trial with the cancer vaccine, ilixadencel, were published in Journal for ImmunoTherapy of Cancer last week. The study showed that when the vaccine is injected into the tumours of newly diagnosed metastatic kidney cancer patients, it provoked a potent immune response to the disease. In addition, […]

read more
Showing all 5 results